Defining the clinical course of multiple sclerosis: Results of an international survey
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Standardization of terminology used to describe the pattern and course of MS is essential for mutual understanding between clinicians and investigators. It is particularly important in design of, and recruitment for, clinical trials statistically powered for expected outcomes for given patient populations with narrowly defined entry criteria. For agents that prove safe and effective for MS, knowledge of the patient populations in definitive clinical trials assists clinicians in determining who may ultimately benefit from use of the medication. An international survey of clinicians involved with MS revealed areas of consensus about some terms classically used to describe types of the disease and other areas for which there was lack of consensus. In this report, we provide a summary of the survey results and propose standardized definitions for the most common clinical courses of patients with MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Schumacher, G. A., Beebe, G., Kibler, R. F., Kurland, L. T., Kurtzke, J. F., McDowell, F., Nagler, B., Sibley, W. A., Tourtellotte, W. W., & Willmon, T. L. (1965) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1965.tb20235.x · Cited by 1,438
Major differences in the dynamics of primary and secondary progressive multiple sclerosis
Thompson, A. J., Kermode, A. G., Wicks, D., MacManus, D. G., Kendall, B. E., Kingsley, D. P. E., & McDonald, W. I. (1991) · Annals of Neurology · doi:10.1002/ana.410290111 · Cited by 486
SERIAL GADOLINIUM ENHANCED MAGNETIC RESONANCE IMAGING IN MULTIPLE SCLEROSIS
MILLER, D. H., RUDGE, P., JOHNSON, G., KENDALL, B. E., MACMANUS, D. G., MOSELEY, I. F., BARNES, D., & MCDONALD, W. I. (1988) · Brain · doi:10.1093/brain/111.4.927 · Cited by 407
Autosomal dominant cerebellar phenotypes: The genotype has settled the issue
Rosenberg, R. N. (1995) · Neurology · doi:10.1212/wnl.45.1.1 · Cited by 402
Megadose corticosteroids in multiple sclerosis
Kupersmith, M. J., Kaufman, D., Paty, D. W., Ebers, G., McFarland, H., Johnson, K., Reingold, S., & Whitaker, J. (1994) · Neurology · doi:10.1212/wnl.44.1.1 · Cited by 386
Self-citationEDMUS, a European database for multiple sclerosis.
Confavreux, C., Compston, D. A., Hommes, O. R., McDonald, W. I., & Thompson, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.8.671 · Cited by 313
NAESER, M. A., PALUMBO, C. L., HELM-ESTABROOKS, N., STIASSNY-EDER, D., & ALBERT, M. L. (1989) · Brain · doi:10.1093/brain/112.1.1 · Cited by 298
Willoughby, E. W., Grochowski, E., Li, D. K. B., Oger, J., Kastrukoff, L. F., & Paty, D. W. (1989) · Annals of Neurology · doi:10.1002/ana.410250107 · Cited by 254
Outcomes assessment in multiple sclerosis clinical trials: a critical analysis
Whitaker, J., McFarland, H., Rudge, P., & Reingold, S. (1995) · Multiple Sclerosis Journal · doi:10.1177/135245859500100107 · Cited by 236
Self-citationDuchenne muscular dystrophy: High frequency of deletions
Bartlett, R. J., Pericak-Vance, M. A., Koh, J., Yamaoka, L. H., Chen, J. C., Hung, W. Y., Speer, M. C., Wapenaar, M. C., B. Van Ommen, G. J., Bakker, E., et al. (1988) · Neurology · doi:10.1212/wnl.38.1.1 · Cited by 196
Chronic progressive multiple sclerosis: Serial magnetic resonance brain imaging over six months
Koopmans, R. A., Li, D. K. B., Oger, J. J.-F., Kastrukoff, L. F., Jardine, C. M., Costley, L., Hall, S., Grochowski, E., & Paty, D. W. (1989) · Annals of Neurology · doi:10.1002/ana.410260211 · Cited by 91
Accumulation of hydrocarbon in a patient with adrenoleukodystrophy
Hiroshi, M. I. K. I., Matsuzawa, Y., Ishibe, T., Ishikawa, K., Moriwaki, K., Takahashi, M. P., TSUMORI, T., Yamamoto, A., & Tarui, S. (1983) · Journal of Neurology · doi:10.1007/bf00313491 · Cited by 12
Cited by
New Multiple Sclerosis Phenotypic Classification
Lublin, F. D. (2014) · European Neurology · doi:10.1159/000367614 · Cited by 4,259
Self-citationA Randomized, Placebo-Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis
Polman, C. H., O'Connor, P. W., Havrdova, E., Hutchinson, M., Kappos, L., Miller, D. H., Phillips, J. T., Lublin, F. D., Giovannoni, G., Wajgt, A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa044397 · Cited by 3,386
Self-citationDefining the clinical course of multiple sclerosis: The 2013 revisions
Lublin, F. D., Reingold, S. C., Cohen, J. A., Cutter, G. R., Sørensen, P. S., Thompson, A. J., Wolinsky, J. S., Balcer, L. J., Banwell, B., Barkhof, F., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000560 · Cited by 3,177
Self-citationA Placebo-Controlled Trial of Oral Fingolimod in Relapsing Multiple Sclerosis
Kappos, L., Radue, E.-W., O'Connor, P., Polman, C., Hohlfeld, R., Calabresi, P., Selmaj, K., Agoropoulou, C., Leyk, M., Zhang-Auberson, L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909494 · Cited by 2,644
Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis
Cohen, J. A., Barkhof, F., Comi, G., Hartung, H.-P., Khatri, B. O., Montalban, X., Pelletier, J., Capra, R., Gallo, P., Izquierdo, G., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0907839 · Cited by 2,204
Metadata
- Authors
- Lublin, F. D., Reingold, S. C., & National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis*
- Venue
- Neurology
- Published
- 1996-04
- Volume
- 46
- Issue
- 4
- Pages
- 907-911
- ISSN
- 0028-3878 (ISSN-L)
- 1526-632X
- OpenAlex
- W2087589796
- Cited by
- 3,686
- References
- 12
- FWCI
- 45.29
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.